Sandra Beaver
TANDEM DIABETES CAREAbout Sandra Beaver
Sandra Beaver, age 48, was appointed as an independent director of Tandem Diabetes Care effective November 7, 2025, with a term through the 2026 Annual Meeting; she joins the Audit Committee and the Cybersecurity and Data Privacy Committee . She is CFO of Lyra Health (since June 2025), and previously served three years as CFO of Evolus; earlier roles included senior finance positions at Experian and IGT; she holds a BBA from the University of Massachusetts and a Professional Designation in Relational Database Design from UCLA . The company will enter into its standard indemnity agreement with her .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Lyra Health | Chief Financial Officer | Began June 2025 | Finance leadership for investor relations, facilities, procurement, corp dev |
| Evolus (public) | Chief Financial Officer | Three years (prior to Lyra) | Public-company CFO experience; capital markets |
| Experian | Senior finance positions | Not disclosed | Global data/technology finance exposure |
| IGT | Senior finance positions | Not disclosed | Global gaming finance exposure |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Lyra Health | CFO | Since June 2025 | Private company leadership; healthcare services |
| Evolus | CFO | Three years | Public medical aesthetics; capital markets and reporting |
| Experian; IGT | Senior finance roles | Not disclosed | Global operational finance |
Board Governance
- Independence: Appointed as an independent director by the Board on Nov 7, 2025 .
- Committee assignments: Audit Committee member; Cybersecurity and Data Privacy Committee member (company also references “Cybersecurity and Data Oversight Committee” in press release) .
- Board structure context: Separate Chair and CEO; independent Chair; board meets executive sessions without management; Audit Committee oversees ESG matters as of 2024 .
- Attendance: 2024 board attendance was 100% for sitting directors; Ms. Beaver was appointed in Nov 2025, so her attendance data is not yet reported .
Fixed Compensation
| Component | Amount | Detail |
|---|---|---|
| Annual Board retainer (cash) | $60,000 | Non-employee director retainer |
| Audit Committee member retainer (cash) | $11,000 | Annual member fee |
| Cybersecurity & Data Privacy Committee member retainer (cash) | $6,000 | Annual member fee |
| Program benchmark (context) | Board $55,000; Audit $11,000; Compensation $9,000; N&CG $7,000; Cybersecurity & Data Privacy Subcommittee $6,000 (members) | 2024 director program levels (pre-appointment) |
Performance Compensation
| Equity Award | Grant Date | Shares/Value | Vesting |
|---|---|---|---|
| Initial RSU onboarding grant | 11/7/2025 | 20,242 shares (valued at $300,000 per policy) | One-third annually on each grant anniversary, subject to continuous service |
| Annual RSU (recurring) | At each Annual Meeting | Aggregate value ≈ $180,000 (shares based on 15-trading-day price calc) | Annual vest (director program), prorated per service since prior meeting |
- Director stock ownership guidelines: Non-employee directors must hold 3x annual director cash retainer; five-year phase-in; calculated excluding unvested RSUs/PSUs and vested unexercised options .
- Hedging/pledging: Prohibited for directors, officers, employees under Insider Trading Policy .
Other Directorships & Interlocks
- No public-company directorships disclosed for Ms. Beaver at appointment; Board expanded from eight to nine upon her appointment .
Expertise & Qualifications
- Finance executive with >20 years in strategic and operational finance across healthcare, medical devices, gaming, enterprise tech, manufacturing .
- Public-company CFO experience (Evolus) and current healthcare CFO (Lyra Health) .
- Academic credentials in business and database design (UMass BBA; UCLA designation) .
Equity Ownership
| Item | Amount | Notes |
|---|---|---|
| RSUs granted (initial onboarding) | 20,242 shares | Unvested; vests one-third annually |
| Annual RSU eligibility | ≈ $180,000 grant value at each Annual Meeting | Shares determined by 15-day average price |
| Beneficial ownership status | Not yet disclosed in proxy tables | Appointment post-2025 proxy; unvested RSUs typically excluded from beneficial ownership until vest windows per policy |
| Pledging/Hedging | None permitted | Company policy prohibits hedging/pledging |
| Stock ownership guideline | 3x annual director cash retainer; 5-year phase-in | Compliance to be assessed by Compensation Committee annually |
Governance Assessment
- Board effectiveness: Beaver’s Audit Committee seat aligns with her finance background; Audit Committee oversees financial reporting and (since 2024) ESG, strengthening risk oversight linkage to her expertise .
- Cyber oversight: Membership on the Cybersecurity & Data Privacy Committee positions her within critical operational risk oversight for Tandem’s digital health strategy .
- Incentive alignment: Compensation mix is equity-heavy (initial $300k RSU plus ~$180k annual RSU) relative to cash retainers ($60k + committee fees), supporting alignment while time-based vesting avoids pay-for-non-performance risks typical of options .
- Independence & conflicts: Appointment expressly as independent director; 8-K includes no Item 404 related-party transactions regarding Ms. Beaver, and company reports no related-party transactions since Jan 1, 2024 requiring disclosure; robust Related-Party Transaction Policy and clawbacks/ownership guidelines reduce conflict risk .
- RED FLAGS: None disclosed specific to Ms. Beaver at appointment; hedging/pledging is prohibited; standard indemnity agreement executed .
Monitoring items for investors: confirm 2026 proxy inclusion of Beaver’s beneficial ownership and director compensation table; track her committee attendance/engagement post-appointment; assess any evolving interlocks or related-party exposures via future 8-Ks and proxies .